Supplemental Figure 2 from Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer

MLA

Scott Kopetz, et al. Supplemental Figure 2 from Dual Inhibition of EGFR and C-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. Mar. 2023. EBSCOhost, https://doi.org/10.1158/1078-0432.22468070.

APA

Scott Kopetz, Gary E. Gallick, Alain R. Thierry, Michael J. Overman, Cathy Eng, Robert A. Wolff, David G. Menter, Anastasia D. Katsiampoura, David R. Fogelman, Arvind Dasari, Kanwal Raghav, Marc Ychou, Brice Pastor, Feng Tian, Laura Henderson, Zhi-Qin Jiang, Ji Yuan Wu, Nila U. Parikh, & Christine M. Parseghian. (2023). Supplemental Figure 2 from Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. https://doi.org/10.1158/1078-0432.22468070

Chicago

Scott Kopetz, Gary E. Gallick, Alain R. Thierry, Michael J. Overman, Cathy Eng, Robert A. Wolff, David G. Menter, et al. 2023. “Supplemental Figure 2 from Dual Inhibition of EGFR and C-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer,” March. doi:10.1158/1078-0432.22468070.